Loading clinical trials...
Loading clinical trials...
A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF PF-04449913, AN ORAL HEDGEHOG INHIBITOR, ADMINISTERED AS SINGLE AGENT IN SELECT HEMATOLOGIC MALIGNANCIES
Conditions
Interventions
PF-04449913
Locations
6
United States
UCSD Medical Center - La Jolla
La Jolla, California, United States
Moores UCSD Cancer Center
La Jolla, California, United States
UCSD Medical Center - Hillcrest
San Diego, California, United States
The University of Texas M.D. Anderson Cancer Center
Houston, Texas, United States
University of Washington Medical Center, Seattle Cancer Care Alliance
Seattle, Washington, United States
U.O. di Ematologia
Bologna, Italy
Start Date
March 3, 2010
Primary Completion Date
September 26, 2012
Completion Date
February 27, 2013
Last Updated
April 25, 2024
NCT06823167
NCT05011422
NCT07285668
NCT07195916
NCT07162038
NCT07185503
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions